Hepatitis B: An ssessment of current and future treatment options (PDF)

Interferon alfa-2b and the nucleoside analog lamivudine are the currently available options for treating chronic hepatitis B virus (HBV) infection. This article reviews major efficacy findings with these agents, defines their role according to patients' clinical status, and provides the latest data on optimal duration of therapy, predictors of response, and long-term effects. The authors also explore the emergence of hepatitis B immune globulin for post-liver transplant HBV prophylaxis and offer a progress report on experimental therapies for chronic HBV infection.